HEREDITARY ANGIOEDEMA
Clinical trials for HEREDITARY ANGIOEDEMA explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Gene-Editing shot aims to stop sudden swelling attacks
Disease control OngoingThis study tests a one-time gene-editing therapy called NTLA-2002 for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. About 80 participants aged 16 and older will receive either the treatment or a placebo to see if it reduces the…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:45 UTC
-
New HAE drug switch study aims for safer monthly shots
Disease control OngoingThis study checks if it's safe for people aged 12 and older with hereditary angioedema (HAE) to switch from their current preventive treatment to a new monthly injection called garadacimab. About 18 participants will receive garadacimab for around 3 months, and researchers will m…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE4 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
New hope for swelling disorder: experimental drug enters human trials
Disease control OngoingThis study tests a new drug called ADX-324 for hereditary angioedema, a genetic condition that causes sudden, painful swelling attacks. The trial has two parts: first, healthy volunteers receive a single dose to check safety; second, patients with the condition receive multiple d…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE1, PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:39 UTC
-
Lifeline for HAE patients: study offers continued access to promising drug
Disease control ENROLLING_BY_INVITATIONThis study provides ongoing access to berotralstat for up to 139 people with hereditary angioedema (HAE) who previously took part in berotralstat trials. The main goal is to monitor safety and side effects over time. Participants take the medication daily to help control their co…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 08:38 UTC
-
Gene therapy for HAE: Long-Term Follow-Up begins
Disease control ENROLLING_BY_INVITATIONThis study follows 100 people with hereditary angioedema (HAE) who previously received the experimental gene therapy NTLA-2002. Researchers will track side effects and how well the treatment controls swelling attacks over time. The goal is to understand the long-term safety and l…
Matched conditions: HEREDITARY ANGIOEDEMA
Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:33 UTC
-
New hope for kids with rare swelling disorder: daily pill may prevent attacks
Disease control OngoingThis study tests a daily medication called berotralstat in children aged 2 to under 12 who have hereditary angioedema (HAE), a rare condition that causes sudden, painful swelling attacks. The goal is to find the right dose based on the child's weight and to check if the drug is s…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 08:29 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema patients
Disease control ENROLLING_BY_INVITATIONThis study tests an oral medication called deucrictibant for quickly treating sudden swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have completed earlier studies or are new to the drug will take the p…
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug shows promise in preventing painful swelling attacks for HAE patients
Disease control OngoingThis study tests a medicine called donidalorsen for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug is safe and effective over the long term at preventing these attacks and improving quality of life. About …
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
New pill shows promise for controlling rare swelling disorder
Disease control OngoingThis study looks at the long-term safety of an oral medication called KVD900 for treating sudden swelling attacks in people with hereditary angioedema (HAE) types I or II. About 145 adolescents and adults who previously took part in a related study will take KVD900 as needed for …
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE3 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Gene therapy aims to stop painful swelling attacks in rare disease
Disease control OngoingThis study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene-editing to reduce a protein that triggers attacks. Researchers are checking safety and how well it works …
Matched conditions: HEREDITARY ANGIOEDEMA
Phase: PHASE1, PHASE2 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:02 UTC